Lumos Diagnostics Holdings Ltd

Lumos Diagnostics has a market price of $0.15 and a market cap of $138.58 million, with a price-to-book ratio of 22.51 and a price-to-tangible-book ratio of 22.51. The company's enterprise value to EBITDA is -21.92, and its enterprise value to revenue is 11.58. The company's return on equity is -1.17, and its return on assets is -0.35, indicating poor profitability relative to its equity and asset base. The company's capital structure is characterized by a debt-to-equity ratio of 1.13, with total liabilities of $14.66 million and total equity of $6.16 million. The company has $1.96 million in cash and equivalents, but its operating cash flow is negative at -$9.33 million, and its free cash flow is -$4.71 million. The current ratio is 0.74, suggesting liquidity constraints. Lumos Diagnostics reported revenue of $12.40 million, with a gross profit of $7.81 million. However, the company incurred an operating loss of $6.55 million and a net loss of $7.18 million. These figures indicate that the company is not yet profitable and is operating at a loss despite generating gross profit. The company's revenue is concentrated in its core diagnostic test products, with no disclosed geographic diversification. The company's business is primarily focused on the development and commercialization of point-of-care diagnostic tests, with no significant diversification into other product lines or markets. The company's growth trajectory is uncertain, with a net loss of $7.18 million and a negative operating cash flow of $9.33 million. The company's revenue of $12.40 million is below the analyst estimate of $16.04 million, indicating potential challenges in meeting revenue expectations. The company faces liquidity and dilution risks, with a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, and there are no disclosed dilution sources in the recent filings or transcripts.